Vanda Pharmaceuticals (VNDA) Revenue Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.77% |
| Dec 31, 2025 | -3.30% |
| Sep 30, 2025 | -1.38% |
| Jun 30, 2025 | -3.30% |
| Mar 31, 2025 | -2.91% |
| Dec 31, 2024 | -2.68% |
| Sep 30, 2024 | -4.34% |
| Jun 30, 2024 | -3.09% |
| Mar 31, 2024 | -0.11% |
| Dec 31, 2023 | -3.12% |
| Sep 30, 2023 | -4.61% |
| Jun 30, 2023 | -0.55% |
| Mar 31, 2023 | 7.47% |
| Dec 31, 2022 | 7.81% |
| Sep 30, 2022 | 9.58% |
| Jun 30, 2022 | 8.89% |
| Mar 31, 2022 | 9.98% |
| Dec 31, 2021 | 12.21% |
| Sep 30, 2021 | 12.74% |
| Jun 30, 2021 | 13.51% |
| Mar 31, 2021 | 13.51% |
| Dec 31, 2020 | 16.26% |
| Sep 30, 2020 | 16.30% |
| Jun 30, 2020 | 17.66% |
| Mar 31, 2020 | 21.23% |
| Dec 31, 2019 | 31.71% |
| Sep 30, 2019 | 32.11% |
| Jun 30, 2019 | 40.31% |
| Mar 31, 2019 | 39.16% |
| Dec 31, 2018 | 43.28% |
| Sep 30, 2018 | 41.35% |
| Jun 30, 2018 | 41.60% |
| Mar 31, 2018 | 40.13% |
| Dec 31, 2017 | 41.09% |
| Sep 30, 2017 | 37.90% |
| Jun 30, 2017 | 38.08% |
| Mar 31, 2017 | 35.67% |
| Dec 31, 2016 | 35.51% |
| Sep 30, 2016 | 37.02% |
| Jun 30, 2016 | 37.13% |
| Mar 31, 2016 | 34.70% |
| Dec 31, 2015 | 53.90% |
| Sep 30, 2015 | 31.36% |
| Jun 30, 2015 | 78.04% |